Danicopan
Voydeya (danicopan) is a small molecule pharmaceutical. Danicopan was first approved as Voydeya on 2024-03-29.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Voydeya
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Danicopan
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VOYDEYA | Alexion Pharmaceuticals | N-218037 RX | 2024-03-29 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| voydeya | New Drug Application | 2024-04-03 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
28 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Paroxysmal hemoglobinuria | D006457 | Orphanet_447 | D59.12 | — | 4 | 3 | — | 1 | 8 |
| Hemoglobinuria | D006456 | — | R82.3 | — | 4 | 3 | — | 1 | 8 |
| Hemolysis | D006461 | — | — | — | — | 2 | — | 1 | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glomerulonephritis | D005921 | HP_0000099 | N05 | — | 3 | — | — | 1 | 4 |
| Membranoproliferative glomerulonephritis | D015432 | — | — | — | 3 | — | — | 1 | 4 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | 1 | — | — | — | 1 |
| Geographic atrophy | D057092 | — | — | — | 1 | — | — | — | 1 |
| Atrophy | D001284 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 13 | — | — | — | — | 13 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Danicopan |
| INN | danicopan |
| Description | Danicopan, sold under the brand name Voydeya, is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria. It is a complement inhibitor which reversibly binds to factor D to prevent alternative pathway-mediated hemolysis and deposition of complement C3 proteins on red blood cells.
|
| Classification | Small molecule |
| Drug class | complement receptor antagonists/complement inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)c1nn(CC(=O)N2C[C@H](F)C[C@H]2C(=O)Nc2cccc(Br)n2)c2ccc(-c3cnc(C)nc3)cc12 |
Identifiers
| PDB | — |
| CAS-ID | 1903768-17-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4250860 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15401 |
| UNII ID | JM8C1SFX0U (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 135 documents
View more details
Safety
Black-box Warning
Black-box warning for: Voydeya
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use